Mission: The Bioanalytical Laboratory (BL) is a heavily used shared resource of the Comprehensive Cancer Center with a mission to provide access to advanced analytical services, technologies and scientific consultation for DNA, protein, and lipid chemistry. The BL specializes in discovery, identification, characterization, and quantification of biomolecules including: structural analysis of proteins, peptides and lipids by mass spectrometry and biochemical methods;DNA sequence analysis;DNA/RNA synthesis; chromatography of proteins, peptides, DNA, and lipids;and quantification of clinical biomarkers in tissue and blood specimens. Assets: Assets of the BL include more than 10 major instrument systems and the expertise of its staff members. Co-directors, Drs. Mark Lively and Michael Thomas, are expert chemists with more than 50 years of combined experience in research and core laboratory management. Dr. Thomas is a lipid mass spectrometry expert. Dr. Lively is a founding member and former president of the Association of Biomolecular Resource Facilities (ABRF). He is a member of the National Advisory Research Resources Council of the NIH National Center for Research Resources. The BL technicians have more than 80 years of combined laboratory experience. Usage: The BL supported the research of 73 Center members from 11/2009 -10/2010, analyzing 10,234 samples. The most heavily used services were: mass spectrometry methods (4,018 spls);DNA sequencing (4,299 spIs);biomarker HPLC (746 spIs);protein/peptide methods (248 spIs);and DNA synthesis (182 spIs). Center members received 60% of the services performed. Future directions: The BL recently added two important new mass spectrometers, a ThermoFisher TSQ Discovery Max electrospray, triple quadrupole mass spectrometer, to enhance the study of polar lipids and a ThermoFisher TSQ Quantum XLS triple quadrupole gas-chromatograph (GC) mass spectrometer. An Advion Nanomate? source was acquired for the Q-TOF mass spectrometer for proteomics. These instruments permit the BL to provide new and improved MS services of lipids, proteins, and peptides. Clinical biomarker analysis services will be expanded to enhance support of ongoing clinical studies.

Public Health Relevance

The BL is widely used by Center investigators from each program: 15 from Cell Growth and Survival;13 from Cellular Damage and Defense;and 7 from the Clinical Research Program. BL services provide specialized technologies to identify and characterize biological molecules to enable understanding their roles in basic biochemical mechanisms of cancer, cell proliferation, cell signaling, and DNA damage. The central availability of these shared resources insures availability, stability, reliability, and quality control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA012197-38S3
Application #
8724653
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
38
Fiscal Year
2013
Total Cost
$2,601
Indirect Cost
$901
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Mirlohi, Susan; Duncan, Susan E; Harmon, Michele et al. (2015) Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Clin Oral Investig 19:127-37
Gmeiner, William H; Jennings-Gee, Jamie; Stuart, Christopher H et al. (2015) Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leuk Res 39:229-35
Sohl, Stephanie J; Levine, Beverly; Avis, Nancy E (2015) Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for early post-treatment breast cancer survivors. Qual Life Res 24:205-12
Gmeiner, William H; Boyacioglu, Olcay; Stuart, Christopher H et al. (2015) The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2. Prostate 75:360-9
Randle, Reese W; Doud, Andrea N; Levine, Edward A et al. (2015) Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 22:1634-8
Doud, Andrea N; Randle, Reese W; Clark, Clancy J et al. (2015) Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 22:1645-50
Yosipovitch, Gil; Mills, Kyle C; Nattkemper, Leigh A et al. (2014) Association of pain and itch with depth of invasion and inflammatory cell constitution in skin cancer: results of a large clinicopathologic study. JAMA Dermatol 150:1160-6
Milliron, Brandy-Joe; Vitolins, Mara Z; Tooze, Janet A (2014) Usual dietary intake among female breast cancer survivors is not significantly different from women with no cancer history: results of the National Health and Nutrition Examination Survey, 2003-2006. J Acad Nutr Diet 114:932-7
Jordan, Jennifer H; D'Agostino Jr, Ralph B; Hamilton, Craig A et al. (2014) Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonan Circ Cardiovasc Imaging 7:872-9
Vatca, M; Lucas Jr, J T; Laudadio, J et al. (2014) Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol 50:869-76

Showing the most recent 10 out of 161 publications